恩替卡韦治疗慢性乙型肝炎53例疗效分析

徐瑞芳; 张志锋; 张曹庚; 殷秋炯; 刘红

恩替卡韦治疗慢性乙型肝炎53例疗效分析

Efficacy analysis of entecavir to 53 chronic hepatitis B patients

摘要

摘要: 目的:评价恩替卡韦治疗慢性乙型肝炎(CHB)12个月的疗效和安全性。方法:选择CHB患者53例给予恩替卡韦0.5 mg/d抗病毒治疗12个月,53例患者治疗前乙型肝炎病毒(HBV)DNA载量分为107～109、105～106、104copies/L进行分层,分别观察服药后1、3、6、12个月时HBV DNA载量,丙氨酸氨基转氨酶(ALT)、天门冬氨酸氨基转氨酶(AST)变化情况。结果:恩替卡韦对治疗前HBV DNA载量分别为107～109、105～106、104均具有较强的抑制作用;治疗后随着时间推移HBV DNA载量下降越明显,治疗前HBV DNA载量越低服药后HBV DNA载量越快达到正常值,治疗前后差异均有统计学意义(P0.05～P0.01)。恩替卡韦抑制HBV DNA的同时伴随ALT、AST的下降,治疗前HBV DNA载量越低,治疗后12个月ALT、AST复常率越高,治疗前后差异均有统计学意(P0.05～P0.01)。结论:恩替卡韦对CHB患者HBV有很强的抑制作用,在抑制病毒复制的同时能改善肝功能。

Abstract: Objective:To evaluate the efficacy and safety of entecavir to chronic hepatitis B(CHB).Methods:Fifty-three patients who had been treated with entecavir(0.5 mg/d) for 12 months were divided into three groups:HBV DNA 107～109 copies/L,HBV DNA 105～106 copies/L,HBV DNA 104 copies/L.Fasting venous blood were collected from each patient after treatment of 1,3,6 and 12 months for detection of hepatitis B viral(HBV) load DNA,alanine aminotransferase(ALT),aspartate transaminase(AST).Results:As the duration of treatment,HBV DNA,ALT,and AST all decreased significantly(P 0.05).three markers were all significantly lower after 1 month treatment than before treatment.Three markers were also significantly lower after 3 month treatment than that after 1 month treatment.As well as,three markers were significantly lower after 12 month treatment than that after 3 month treatment.Additionally,compared with high viral loads group,HBV DNA,ALT,and AST converted negative earlier in lower viral loads group(P 0.05 to P 0.01).Conclusions:Entecavir can suppress HBV replication and improve liver function of the patients.

HTML全文

参考文献(5)

施引文献

资源附件(0)